

# Connectivity Map

An introduction

Speaker

Roger Yang

楊伍隆

Advisors

Prof. Kun-Mao Chao

趙坤茂

Prof. Chi-Ying Huang

黃奇英

May 14, 2012

# References

## The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease

Justin Lamb,<sup>1\*</sup> Emily D. Crawford,<sup>1†</sup> David Peck,<sup>1</sup> Joshua W. Modell,<sup>1</sup> Irene C. Blat,<sup>1</sup> Matthew J. Wrobel,<sup>1</sup> Jim Lerner,<sup>1</sup> Jean-Philippe Brunet,<sup>1</sup> Aravind Subramanian,<sup>1</sup> Kenneth N. Ross,<sup>1</sup> Michael Reich,<sup>1</sup> Haley Hieronymus,<sup>1,2</sup> Guo Wei,<sup>1,2</sup> Scott A. Armstrong,<sup>2,3</sup> Stephen J. Haggarty,<sup>1,4</sup> Paul A. Clemons,<sup>1</sup> Ru Wei,<sup>1</sup> Steven A. Carr,<sup>1</sup> Eric S. Lander,<sup>1,5,6</sup> Todd R. Golub<sup>1,2,3,5,7\*</sup> [Science 313\(5795\): 1929-1935.](#)

Cited in Scopus: 489 (as Oct 10, 2011)

Cited in Scopus: 73 (as Oct 10, 2011)


### INNOVATION

## The Connectivity Map: a new tool for biomedical research

*Justin Lamb*


[Nature Reviews Cancer 7\(1\): 54-60.](#)

# Goals



- ▶ Create a large drug-response profile database.
- ▶ Use microarray profiles to query best matching or mismatching drugs
- ▶ Drug repurposing

# Goals




Gene	Control	Treatment	Fold Change
A	1	5	5/1
B	1	1	1/1
C	5	1	1/5
...			

measurement of  
mRNA


	Drug 1	Drug 2	Drug 3	Drug ...	Drug N
Gene 1					
Gene 2					
Gene 3					
Gene 4					
Gene 5					
Gene 6					
Gene ...					
Gene M					

# Drug Similarity



# Drug Repurposing

# Drug Development Process




[http://www.msd.com.hk/health\\_info/drug\\_education/e\\_ddp\\_introduction.html](http://www.msd.com.hk/health_info/drug_education/e_ddp_introduction.html)



**a**

*De novo* drug discovery and development


- 10–17 year process
- <10% overall probability of success




**b**

Drug repositioning

- 3–12 year process
- Reduced safety and pharmacokinetic uncertainty



Ashburn, Ted T, and Karl B Thor. 2004. "Drug repositioning: identifying and developing new uses for existing drugs." *Nature Reviews Drug Discovery* 3(8): 673–683.



Hughes, Bethan. 2010. "2009 FDA drug approvals." *Nature Reviews Drug Discovery* 9(2): 89–92.

- 2007: 69 drugs, but 16 are new drugs
- average 15 years and US\$800 million for a new drug to market
- New drugs approved by FDA each year remain at 20~30 compounds.

# New uses for old drugs

## New uses for old drugs

It takes too long and costs too much to bring new drugs to market. So let's beef up efforts to screen existing drugs for new uses, argue Curtis R. Chong and David J. Sullivan Jr.



Chong, Curtis R, and David J Sullivan. 2007. "New uses for old drugs." *Nature* 448(7154): 645–646.

“The most fruitful basis for the discovery of a new drug is to start with an old drug”  
-- Nobel laureate James Black


# Drug repurposing examples

- Nelfinavir for cancer
- Tamoxifen for bipolar disorder
- Gleevec for rheumatoid arthritis
- Pentylentetrazole for Down Syndrome
- Astemizole for malaria
- Lipitor for alzhemimers
- Lipitor for influenza mortality
- Metformin for cancer

CDD Community Group Meeting, SFO,  
Oct 1, 2009


# Database

# Drugs



- ▶ 1309 small molecules
- ▶ 680 drugs have been conducted 4 times each.
- ▶ 6100 instances
- ▶ 7056 microarrays


# Drug dosage



- ▶ Most drugs are tested between 1 μM and 20 μM


# Dose count

Instance Count v.s. Number of Doses






# Duration




- ▶ Most drugs are conducted for 6 hours.
- Primary effects, not second effects

# Cell Type



MCF7	Breast cancer
PC3	Prostate Cancer
HL60	Leukemia
ssMCF7	Breast cancer charcoal-stripped serum
SKMEL5	Skin Cancer

# Fold Change




▶ 64% of 6100 instances have less than 2% of probes having 2-Fold change.



# Instances

- ▶ Each instance is defined as one drug treatment over a sample of controls.
  - e.g. cells treated with vorinostat versus untreated ones.
- ▶ Instance = Drug type x Cell type x Duration x Dose
  - e.g. 10 $\mu$ M vorinostat on MCF7 for 6 hours
- ▶ 6100 instances over 1309 drugs






Lamb, J et al. 2006. "The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease." *Science* 313(5795): 1929–1935.



Lamb, Justin. 2007. "The Connectivity Map: a new tool for biomedical research." *Nature Reviews Cancer* 7(1): 54–60.

# Drug-Drug similarity




Input: 13 HDAC gene signature

Lamb, J et al. 2006. "The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease." *Science* 313(5795): 1929–1935.



# Drug-disease



Lamb, J et al. 2006. "The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease." *Science* 313(5795): 1929–1935.

Sirolimus reverses gluco-corticoid resistance in acute lymphoblastic leukemia.

# Databases

STRING	<a href="http://string-db.org/">http://string-db.org/</a>
KEGG	<a href="http://www.genome.jp/kegg/">http://www.genome.jp/kegg/</a>
PubChem	<a href="http://pubchem.ncbi.nlm.nih.gov/">http://pubchem.ncbi.nlm.nih.gov/</a>
DrugBank	<a href="http://www.drugbank.ca/">http://www.drugbank.ca/</a>
PubMed	<a href="http://www.ncbi.nlm.nih.gov/pubmed">http://www.ncbi.nlm.nih.gov/ pubmed</a>